miRNA-34b Inhibits Prostate Cancer through Demethylation, Active Chromatin Modifications, and AKT Pathways by �옣�씤�씡
2013;19:73-84. Published OnlineFirst November 12, 2012.Clin Cancer Res 
  
Shahana Majid, Altaf A. Dar, Sharanjot Saini, et al. 
  
Chromatin Modifications, and AKT Pathways
miRNA-34b Inhibits Prostate Cancer through Demethylation, Active
  
Updated version
  
 10.1158/1078-0432.CCR-12-2952doi:
Access the most recent version of this article at:
  
Material
Supplementary
  
 http://clincancerres.aacrjournals.org/content/suppl/2012/11/12/1078-0432.CCR-12-2952.DC1.html
Access the most recent supplemental material at:
  
  
  
  
  
Cited Articles
  
 http://clincancerres.aacrjournals.org/content/19/1/73.full.html#ref-list-1
This article cites by 48 articles, 16 of which you can access for free at:
  
Citing articles
  
 http://clincancerres.aacrjournals.org/content/19/1/73.full.html#related-urls
This article has been cited by 1 HighWire-hosted articles. Access the articles at:
  
  
  
E-mail alerts  related to this article or journal.Sign up to receive free email-alerts
  
Subscriptions
Reprints and 
  
.pubs@aacr.org
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at
  
Permissions
  
.permissions@aacr.org
To request permission to re-use all or part of this article, contact the AACR Publications Department at
on May 18, 2014. © 2013 American Association for Cancer Research. clincancerres.aacrjournals.org Downloaded from 
Published OnlineFirst November 12, 2012; DOI: 10.1158/1078-0432.CCR-12-2952 
Human Cancer Biology
miRNA-34b Inhibits Prostate Cancer through Demethylation,
Active Chromatin Modiﬁcations, and AKT Pathways
Shahana Majid1, Altaf A. Dar2, Sharanjot Saini1, Varahram Shahryari1, Sumit Arora1, Mohd Saif Zaman1,
Inik Chang1, Soichiro Yamamura1, Yuichiro Tanaka1, Takeshi Chiyomaru1, Guoren Deng1, and Rajvir Dahiya1
Abstract
Purpose:miRNAs can act as oncomirs or tumor-suppressormiRs in cancer. This studywas undertaken to
investigate the status and role of miR-34b in prostate cancer.
Experimental Design: Profiling of miR-34b was carried out in human prostate cancer cell lines and
clinical samples by quantitative real-time PCR and in situ hybridization. Statistical analyses were done to
assess diagnostic/prognostic potential. Biological significance was elucidated by carrying out a series of
experiments in vitro and in vivo.
Results:We report thatmiR-34b is silenced inhumanprostate cancer and themechanism is throughCpG
hypermethylation. miR-34b directly targeted methyltransferases and deacetylases resulting in a positive
feedback loop inducing partial demethylation and active chromatin modifications. miR-34b expression
could predict overall and recurrence-free survival such that patients with high miR-34b levels had longer
survival. Functionally, miR-34b inhibited cell proliferation, colony formation, migration/invasion, and
triggered G0/G1 cell-cycle arrest and apoptosis by directly targeting the Akt and its downstream proliferative
genes.miR-34b caused adecline in themesenchymalmarkers vimentin, ZO1,N-cadherin, and Snail with an
increase in E-cadherin expression, thus inhibiting epithelial-to-mesenchymal transition. Finally we showed
the antitumor effect of miR-34b in vivo. MiR-34b caused a dramatic decrease in tumor growth in nude mice
compared with cont-miR.
Conclusion: These findings offer new insight into the role ofmiR-34b in the inhibition of prostate cancer
through demethylation, active chromatin modification, and Akt pathways and may provide a rationale for
the development of new strategies targeting epigenetic regulation of miRNAs for the treatment of prostate
cancer. Clin Cancer Res; 19(1); 73–84. 2012 AACR.
Introduction
miRNAs are non–protein-coding RNAs thought to regu-
late the expression of up to 90% of human genes (1).
Growing evidence has strongly implicated the involvement
of miRNAs in carcinogenesis (2, 3). Dysregulated miRNAs
may function as oncogenes (4), such as the miR-17–92
cluster (5), or tumor suppressor genes such as miR-205 (6–
8). A single miRNA can have hundreds of target mRNAs,
highlighting the importance of this gene regulation system
in cellular functions (9). The study of miRNAs has become
the subject of intense interest, especially after the discovery
of their fundamental role in a myriad of cellular and
biological processes ranging from development to disease
(10). From a clinical point of view, miRNAs have great
potential as diagnostic and therapeutic agents. Because
microarray analysis shows a general downregulation of
miRNAs in tumors when compared with normal tissues
(11). As a result of the remarkable tissue specificity of
miRNAs, they have become a very useful tool for defining
the origin of tumors in poorly differentiated cancers (12).
The prognosis and survival of patients depend on the stage
of the cancer at diagnosis. For this reason, 1 of the most
important issues in clinical cancer research is to find early
biomarkers of the tumorigenic process. miRNA signatures
have been reported to be powerful tools for early diagnosis
in renal cancer and have been found to distinguish between
metastatic and nonmetastatic tumors. The 5-year survival
rate of patients with primary metastasis was reported to be
10% as compared with 70% to 90% in nonmetastatic
patients (13).
Among various epigenetic mechanisms of cancer-related
gene silencing, DNA hypermethylation of CpG sites within
CpG islands is known to lead to the inactivation of many
tumor suppressor miRNAs (14). Previous reports have
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shown that disruption of DNA methylation in cancer cell
lines induces upregulation of substantial numbers of miR-
NAs (15, 16) and, thus, helps identify candidate tumor
suppressor miRNAs that are silenced by methylation. For
example, treatment of bladder cancer cells with histone
deacetylase (HDAC) and DNA methyltransferase (DNMT)
inhibitors induced demethylation and re-expression of
miRNA-127 (17). Similarly miR-34b/c was found to be
methylated and downregulated in colorectal and gastric
cancers (16, 18). The DNA methylation profile of tumors
can be used as a signature to define tumor type, clinical
prognosis, and treatment response (19, 20). MiRNAs
transcribed from CpG islands undergo DNA methylation-
associated repression with a similar chromatin context to
protein-coding genes (15, 16, 21). Epigenetic regulation of
miRNA genes is tightly linked to chromatin signatures and
transcriptionally active miRNA genes are characterized by
active chromatin marks, such as trimethylated histone H3
lysine 4 (3H3K4; ref. 22). Epigenetic silencing of miRNAs is
also involved in the acquisition of an invasive phenotype
and the development of metastasis (23). Inactivation of
tumor-promotingmiRNAs (24, 25) or restoration of tumor-
suppressor miRNAs (15, 17, 26) has great potential for use
in cancer treatment.
Here we report that: (i) miR-34b is significantly down-
regulated in prostate cancer and themechanismof silencing
is through CpG hypermethylation; (ii) reconstitution of
miR-34b induced partial demethylation and active chro-
matin modifications in upstream sequence of miR-34b
gene; (iii) miR-34b acts as a tumor suppressor miRNA in
prostate cancer, (iv) miR-34b has antiproliferative effects
and targets Akt pathway genes; (v) miR-34b has antimigra-
tory/-invasive effects and downregulates markers of epithe-
lial-to-mesenchymal transition (EMT); and (vi) miR-34b
suppresses tumor growth in an in vivo xenograft nudemouse
model.
Materials and Methods
Cell culture, plasmids, and probes
Human prostate cancer cell lines PC3, LNCaP, and a
nonmalignant renal cell line RWPE1 were obtained from
the American Type Culture Collection (ATCC; Manassas,
Virginia) and grown according to the ATCC protocol and as
described previously (7). These human-derived cell lines
were authenticated byDNA short-tandem repeat analysis by
the ATCC. The experiments with cell lines were carried out
within 6 months of their procurement/resuscitation. Plas-
mids of 30-UTR target expression clones were purchased
fromGeneCopoeia. TaqMan probes andmiRNA precursors
were purchased from Applied Biosystems. The probes for
methylation-specific real-time PCR were synthesized by
Applied Biosystems, then labeled with 6FAM reporter at
the 50-end and with MGB quencher at the 30-end.
Quantitative real-time PCR and in situ hybridization
Tissue samples from radical prostectomy were obtained
from the Veterans Affairs Medical Center, San Francisco,
California. Written informed consent was obtained from all
patients and the study was approved by the UCSF Commit-
tee onHuman Research (Approval number: H9058–35751-
01). Laser capture microdisection was employed to get total
RNA. All reactions were run in a 7500 Fast Real Time PCR
System and miRNA assays were conducted in accordance
with the manufacturer’s instructions (Applied Biosystems).
Relative expression was calculated using comparative Ct.
In situ hybridization (ISH) was carried out as described
previously (7). The detailed method is described in Sup-
plementary Materials and Methods. ISH results for tissue
array were graded according to quick score (percentage of
cells stained  intensity of stain) and normalized to U6
levels.
Methylation analysis of miR-34b by sequencing and
quantitative methylation-specific PCR
DNA was available for 32 pairs of laser-capture micro-
disected samples. Out of 32, 19 pairs are from the same
cohort for which miRNA expression was available. Meth-
ylation status of tissue sampleswas analyzed by quantitative
methylation-specific PCR (qMSP) within the 1.0-kb region
upstreamof themiR-34b gene. For prostate cancer cell lines,
methylation was determined by sequencing and percentage
of methylation was calculated. The sequences are given in
Supplementary Table S2.
Immunoblotting and immunofluorescence
Immunoblotting was carried out as described previously
(7) and is also described in Supplementary Materials. For
immunofluorescence, cells were transfectedwith precursors
of miR-34b or cont-miR for 72 hours, washed, and fixed
with acetone–methanol (1:1) mixture. Cells were then
blocked with 10% normal goat serum blocking solution
(Zymed Laboratories) and hybridized with the specific
primary antibodies against EMTmarkers. Cellswerewashed
and hybridized with fluorescein conjugated secondary
Translational Relevance
This study documents the pleiotropic role of miR-34b
in prostate cancer. Our results provide evidence that
miR-34b acts as a tumor suppressor with diagnostic and
prognostic significance in prostate cancer. Reconstitu-
tion of miR-34b downregulated DNAmethyltransferase
(DNMT) and histone deacetylase (HDAC), resulting in
partial demethylation and induction of active chromatin
modifications. miR-34b had antiproliferative and anti-
invasive effect by impairing theAktproliferative pathway
genes and the epithelial-to-mesenchymal transition
markers. We also confirmed the growth-suppressive
effect of miR-34b in in vivo xenografts. These findings
offer novel insight into the association between dysre-
gulation of miRNA and methylation/chromatin modi-
fication and provide a strong rationale for the develop-
ment of new strategies targeting the epigenetic regulation
of miRNAs for the treatment of prostate cancer.
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antibody (1:1,000), then washed and mounted with Pro-
Long Gold antifade reagent with DAPI (Invitrogen-Life
Technologies).
Luciferase assays
For reporter assays, cells were transiently transfected with
wild-type or mutant reporter plasmid and miR-34b or
control-miR. Firefly luciferase activities were measured
using the Dual Luciferase Assay (Promega) 18 hours after
transfection and the results were normalized with Renilla
luciferase. Complementary sequences are given in Supple-
mentary Table S2.
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation (ChIP) assays were
conducted using the EZ-ChIP Kit (Upstate Biotechnology)
as described previously (7). Immunoprecipitation was car-
ried out using antibodies purchased from Upstate Biotech-
nology. Power SYBR Green PCR Mastermix was used to
carry out real-time PCR with a 7500 Fast Real-Time PCR
System (both from Applied Biosystems). Signals were also
confirmed by conventional PCR and gel analyses. Primer
sequences are given in Supplementary Table S2.
Flow cytometry, cell viability, migration, clonability,
and invasion assays
Fluorescence-activated cell sorting (FACS) analysis for
cell cycle and apoptosiswas done72hours after transfection
using nuclear-stain DAPI for cell-cycle analysis or Annexin
V-FITC/7-AAD KIT (Beckman Coulter) for apoptosis anal-
ysis according to the manufacturer’s protocol. Cell viability
was determined at 24, 48, and 72 hours by using the
CellTiter 96 AQueousOne SolutionCell Proliferation Assay
kit (Promega) according to themanufacturer’s instructions.
For colony-formation assay, cells were seeded at lowdensity
(1,000 cells/plate) and allowed to grow until visible colo-
nies appeared. Then, cells were stainedwithGiemsa and the
colonies were counted. The Cytoselect 24-well cell migra-
tion and invasion assay kit (Cell Biolabs) was used for
migration and invasion assays according to the manufac-
turer’s instructions.
In vivo intratumoral delivery of miR-34b
The antitumor effect ofmiR-34bwas determined by local
administration ofmiR-34bprecursor in established tumors.
Eachmousewas injectedwith 5.0106 PC3prostate cancer
cells subcutaneously, and there were 5 mice in each
group. After palpable tumors developed (average volume,
50 mm3), 6.25 mg of synthetic miRNA-34b and/or control
miRNA complexed with 1.6 mL siPORT Amine transfection
reagent (Ambion) in 50 mL PBS was delivered 8 times
intratumorally at 3-day intervals. Tumor growth was fol-
lowed for 21 days from the first injection. All animal care
was in accordance with institutional guidelines.
Statistical analysis
Statistical analyses were conducted with StatView version
5 for Windows, GraphPad Prism 5, and MedCalc version
10.3.2. All quantified data represent an average of at least
triplicate samples or as indicated. Error bars represent
standard deviation of the mean. All tests carried out were
2-tailed, and P values 0.05 or less were considered statisti-
cally significant. Receiver operating curves (ROC) were
calculated to determine the potential of miR-34b or its
methylation to discriminate between malignant and
nonmalignant samples. Chi-square tests were conducted
to determine the correlation among miR-34b expression,
clinicopathologic characteristics, and disease-progression
analysis. Kaplan–Meier (log-rank test) analysis was also
carried out for survival analysis.
Results
Downregulation of miR-34b expression and its
correlation with clinicopathologic characteristics of
patients
ExpressionofmiR-34bwas examined inprostate cell lines
and tissue samples by miRNA-quantitative real-time PCR
(qRT-PCR). The expression of miR-34b was downregulated
in cancer cell lines PC3 and LNCaP compared with the
nonmalignant cell line RWPE1 (Fig. 1A). To examine the
biological significance of miR-34b, its expression was ana-
lyzed in 148 laser-captured microdisected (LCM) matched
human tissue samples (Fig. 1A) together with an
unmatched group of 27 benign prostatic hyperplasia (BPH)
and 20 tumor samples (Supplementary Fig. S1A). To val-
idate the reproducibility of the data, we also carried out in
situ hybridization on commercially available tissue arrays
(Cat.No. PR956;USBiomax) to determinemiR-34b expres-
sion in an independent cohort of tissues samples (Supple-
mentary Fig. S1B). Almost all carcinoma samples showed
significant downregulation of miR-34b expression with
respect to either normal or BPH samples (Fig. 1B, Supple-
mentary Fig. S1A and S1B). Among the 74 pairs of matched
samples, 63 pairs had either significantly lower or no
expression ofmiR-34b (<0.8-fold) in tumors versus normal
samples (P < 0.0001), 3 pairs had equal expression (0.8- to
1.2-fold), whereas 8 pairs had higher miR-23b expression
(>1.2-fold) in tumors comparedwith theirmatched normal
samples. These results suggest that miR-34b is significantly
downregulated andmight be a putative tumor suppressor in
prostate cancer.
Clinical demographics of the study cohorts are summa-
rized in Supplementary Table S1. ON the basis of the
relative expression of miR-34b, we grouped the samples
into low and high miR-34b expression groups and assessed
the correlation with clinicopathologic variables like Glea-
son grade, pathologic stage (pT), and biochemical recur-
rence (Supplementary Fig. S1C). The time of recurrence
was defined as the first postoperative PSA value greater
than 0.1 ng/mL, confirmed by at least 1 undetectable PSA
level (detection limit <0.04 ng/mL) after surgery. Seventeen
patients experienced a biochemical relapse according to this
criterion. A significant correlation was observed between
miR-34b expression and clinical variables. Decreased miR-
34b expression was observed in 96% of cases with higher
miR-34b in Prostate Cancer
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pathologic stage (pT3-pT4) compared with 80% cases of
low pathologic stage (pT2; P < 0.001). To analyze the
correlation with Gleason grade, we divided the samples
into low (4–6), medium (7), and high (8–10) Gleason
grade groups. Lowexpression ofmiR-34bwas found in73%
cases of low, 90% cases of medium, and 100% cases of high
Gleason grade groups (P < 0.0001). In PSA recurrence
patients, 82% of cases had decreased miR-34b expression
compared with 18% cases with high miR-34b expression
(P < 0.0001). These results reveal that the number of cases
with lowmiR-34b expression increases from low-grade, low
pathologic stage to high-grade and high pathologic stage.
Furthermore, PSA recurrence patients also had significantly
low miR-34b expression, suggesting that miR-34b might
have prognostic value in prostate cancer (Supplementary
Fig. S1C).
ROC analyses were conducted to evaluate the capability
of miR-34b to discriminate between normal and tumor
tissues using 148 LCM tissue samples. An area under the
ROC curve (AUC) of 0.973 [P < 0.0001; 95% confidence
interval (95% CI), 0.930–0.993; Fig. 1C] was obtained
suggesting that miR-34b expression can discriminate
between malignant and nonmalignant samples and might
be useful as a diagnostic marker for prostate cancer. To
determine whether miR-34b expression has prognostic
significance, we divided the matched samples into low
(T/N <0.8-fold) and high (T/N >0.8-fold) miR-34b expres-
sion groups and conducted Kaplan–Meier survival analysis.
In Kaplan-Meier analysis, the miR-34b high expression
group displayed significantly higher overall survival prob-
ability compared with the low expression group (log-rank
test, P < 0.02; Fig. 1C). We also analyzed recurrence-free
A
C
D
1.5
1.0
0.5
0.0
10
1
0.1
0.01
0.001
100
80
60
40
20
0
100
90
80
70
60
50
40
100
80
60
40
20
0
(T/N) (Log 10 scale)
RT - PCR
R
el
at
ive
 e
xp
re
ss
io
n
R
el
at
ive
 m
iR
-3
4b
 e
xp
re
ss
io
n
P 
<
 0
.0
00
7
RWPE1  PC3  LNCaP
miR-34b expression T/N
Total matched samples
Low <0.8 fold
Equal 0.8-1.2 fold
High > 1.2 fold
74 pairs
63 pairs
3   pairs
8   pairs  
P < 0.0001 
P < 0.0001 
AUC 0.973
AUC =  0.814
P    < 0.0001    
95% Cl    = 0.697 to 0.900
Group
H
L
Group
PC3
LNCaP
H
L
HR             = 3.3
95% Cl        = 1.3 to 8.7      
P                = 0.02
0.930-0.993
0.0001
100-Specificity
U    M       U    M
Methylation in cell lines
PC3 
CpG sites
LNCaP
Methylation in tissus samples
100
80
60
40
20
0
100
80
60
40
20
0
150
100
50
0
Months
Normal
(n = 32)
Tumar
(n = 32)
%
 M
et
hy
la
tio
n
Months
0       20       40       60       80      100
-42
-39
-34
-29
-25
-12
-10
-2 6
0             50           100           150          200 0      20     40      60     80    100   120   140
0       20       40      60       80     100
p
95% Cl
Se
ns
itiv
ity
Se
ns
itiv
ity
Specificity
Su
rv
iva
l p
ro
ba
bl
ity
 (%
)
Su
rv
iva
l p
ro
ba
bl
ity
 (%
)
ROC for miR-34b expression
ROC for % methylation in tussues
 
%
 M
et
hy
la
tio
n 
pe
r s
am
pl
e
Kaplan–Meier curve for overall survival
P < 0.02
Recurrence-free survival
P 
<
 0
.0
09
B
Figure 1. Downregulation of miR-34b expression, its potential diagnostic and prognostic signiﬁcance, andmethylation status in prostate cancer. A, qRT-PCR
analysis of miR-34b expression levels in prostate cancer and a nonmalignant cell line. B, qRT-PCR analysis of miR-34b expression in 74 pairs of matched
laser-captured microdissected (LCM) tissue samples. C, receiver operating curve (ROC) and Kaplan–Meier analyses for overall and recurrence-free survival
based on miR-34b expression (H- and L-miR-34b, high or low). D, miR-34b methylation status in cell lines and matched tissue samples and ROC for
percentage of methylation in tissues. M, methylated band; U, unmethylated.
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survival and risk of biochemical recurrence. Results indi-
cated that cases that had low miR-34b expression had poor
recurrence-free survival (log-rank test,P<0.02) and ahigher
risk of biochemical recurrence (hazard ratio, 3.3; 95% CI,
1.3–8.7; Fig. 1C). These results suggest that miR-34b can
predict the biochemical recurrence of prostate cancer and
has potential to be a diagnostic/prognostic biomarker,
although a larger sample size is needed to confirm these
results.
Mechanism of miR-34b silencing in prostate cancer is
through CpG hypermethylation
To investigate the mechanism involved in the depleted
levels of miR-34b in prostate cancer, we carried out meth-
ylation analysis on the 1.0-kb upstream sequence of miR-
34b. Primers are shown in Supplementary Table S2. CpG
rich regions were found (Supplementary Fig. S1D) and
further analyzed for methylation status in prostate cancer
cell lines and tissues. Our results show that this sequence is
hypermethylated in prostate cancer cell lines, with an aver-
age methylation percentage of 94% (Fig. 1D). We also
investigated the methylation status of miR-34b in 32 pairs
of matched LCM tissue samples by methylation-specific
qRT-PCR. Our results indicated that the tumor samples had
a higher methylation percentage compared with their nor-
mal counterparts (Fig. 1D). For the 19 pairs of samples
where DNA and miRNA was available, we found a signif-
icant inverse correlation between miR-34b expression and
methylation. Samples with low miR-34b expression had
higher average percentage ofmethylation and vice versa (P<
0.0001; Supplementary Fig. S1E). We also conducted ROC
analysis to evaluate the ability of miR-34b methylation
percentage to distinguish malignant from normal tissues.
The AUC observed was 0.814 (P < 0.0001; 95% CI, 0.697–
0.990; Fig. 1D), showing that the percentage of miR-34b
methylation is can help distinguishmalignant from normal
tissues.
Reconstitution of miR-34b suppresses DNMTs and
HDACs
As miR-34b is epigenetically silenced in prostate cancer
and DNA methylation is linked to histone modifications,
we asked whether reconstitution of miR-34b in cancer cells
could downregulate DNMTs or HDACs. We overexpressed
miR-34b inPC3andLNCaP cells (Fig. 2A).Our results show
downregulation of DNMT1, DNMT3b, HDAC1, HDAC2,
HDAC3, and HDAC4 protein expression in miR-34b-over-
expressing cells compared with negative control (Fig. 2B).
Complimentary sequences for miR-34b in the 30-UTR of
these genes is given in Supplementary Table S2. To deter-
mine whether miR-34b targets these genes directly, we
carried out luciferase reporter activity assays. The results
show that DNMT1, HDAC1, HDAC2, and HDAC4 are
direct targets as the relative luciferase activity was signifi-
cantly decreased with cotransfection of the wild-type 30-
UTRs of these genes together with miR-34b (Fig. 2C). A
decrease in luciferase activity was also observed in the case
of DNMT3b and HDAC3, although it was not significant.
Further, we attenuated miR-34b expression by using anti-
miR-34b in LNCaP cells because these cells had higher
expression than PC3. Depletion of miR-34b in LNCaP cells
rescued the protein expression of these genes (Fig. 2D),
which again confirms that miR-34b targets these genes in
prostate cancer.
Ectopic expression of miR-34b induces partial
demethylation and active chromatin modifications in
50-upstream sequence of the miR-34b gene
Because miR-34b suppressed DNMTs, we looked to see if
its reconstitution could also induce demethylation in pros-
tate cancer cells. Our results show that overexpression of
miR-34b caused partial demethylation of CpG sites in the
50-upstream sequence of the miR-34b gene as methylation
decreased from96 3% in controls to 84 2% inmiR-34b-
transfected cells (Fig. 3A). Epigenetic regulation of miRNA
genes is tightly linked to chromatin signatures and tran-
scriptionally activemiRNA genes are characterized by active
chromatin marks such as trimethylated histone H3 lysine 4
(3H3K4; ref. 22). To investigate whether these active chro-
matinmodifications are induced in epigenetically regulated
miR-34b gene, we conducted ChIP assay by PCR and qRT-
PCR in the same sequence where we determined methyla-
tion. We found enrichment of active chromatin modifica-
tions and a modest decrease in repressive ones (Fig. 3B).
These changes are indicative of active genes and suggest that
overexpression of themiR-34b gene downregulates DNMTs
and HDACs, which in turn causes a positive feedback loop
to induce demethylation and active modifications.
Functional significance of miR-34b in prostate cancer
Next, we determined the functional significance of miR-
34b in prostate cancer by carrying out cell cycle, prolifer-
ation, clonability, migration and invasion assays. A signif-
icant decrease in cell proliferationwas observed over time in
PC3 and LNCaP cells overexpressing miR-34b (Fig. 4A) as
compared with controls. ThemiR-34b-transfected cells also
had low colony-forming ability, as both size and number of
foci in miR-34b-overexpressing cells was reduced when
compared with controls (Fig. 4A). FACS analysis revealed
that re-expression of miR-34b leads to a significant increase
(12–17%) in the number of cells in the G0–G1 phase of the
cell cycle, whereas the S-phase population decreased from
20% to 5% to 8% suggesting that miR-34b causes a G0–G1
arrest in miR-34b-transfected cells (Fig. 4B). FACS analysis
for apoptosis was carried out using Annexin-V-FITC-7-AAD
dye. The percentage of total apoptotic cells (early apoptotic
þ apoptotic) was significantly increased (12–15%) in
response to miR-34b transfection compared with cont-miR
(1%), with a corresponding 16% decrease in the viable cell
population (Fig. 4C). Collectively, these results indicate a
tumor suppressor role of miR-34b in prostate cancer. To
determine the pathway involved in the antiproliferative
effect of miR-34b, we analyzed the protein expression of
Akt proliferative pathway genes after miR-34b overexpres-
sion (Fig. 4D).miR-34b significantly suppressed phosphor-
ylation of AKT(Ser473) and its downstream target GSK3b
miR-34b in Prostate Cancer
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(Ser9), which in turn becomes activated. Activated GSK3b
phosphorylates b-catenin and promotes its degradation. A
decrease was also found in the downstream proliferative
genes cMyc andCyclinD1 (Fig. 4D).We also found thatmiR-
34b directly targets Akt as there was a significant decrease in
the relative luciferase units with cotransfection of the Akt 30-
UTR along with miR-34b (Fig. 4D). These results suggest
that miR-34b exerts antiproliferative effects in prostate
cancer at least partly through the Akt pathway.
miR-34b downregulates EMT markers and suppresses
cell migration and invasion independent of
proliferation
Cell migration and invasion assays revealed that miR-
34b-overexpressing cells were less proficient than controls
in migrating or invading a barrier membrane, with less
absorbance observed at 560 nm (Fig. 5A and B). We exam-
ined the effect of overexpression of miR-34b on EMT
markers and observed a decrease in vimentin, ZO1, N-
cadherin, and Snail (mesenchymal markers) and an
increase in E-cadherin (epithelial marker) (Fig. 5C–D). The
process of EMT is involved in epithelial-derived tumors,
causing them to become invasive and metastatic, and these
results show that miR-34b suppressed EMT markers.
Intratumoral delivery of miR-34b suppresses
tumorigenicity in vivo
Because miR-34b had an antitumor effect in vitro, we
conducted in vivo experiments to determine the effect of
miR-34b by local administration into established tumors.
We measured the expression of miR-34b in harvested
tumors and found that miR-34b expression was significant-
ly higher in tumors receiving miR-34b compared with
controls (Fig. 6A). The tumor volume of miR-34b injected
mice was significantly lower (38mm3) than those receiving
control injections (186 mm3; Fig. 6B) at the termination of
the experiment. These results confirm the in vivo tumor
suppressor effect of miR-34b in a prostate cancer xenograft
model.
Discussion
In this study, we provide evidence that miR-34b is
silenced in prostate cancer and the mechanism is mediated
through CpG hypermethylation. MiR-34b downregulates
DNMTs, HDACs, and induces partial demethylation and
active chromatin modifications in prostate cancer. Low
expression of miR-34b can predict overall and recurrence-
free survival and can distinguish normal from malignant
tissues. We also elucidated the tumor suppressor role of
miR-34b in prostate cancer and determined that the anti-
proliferative and antimigratory/invasive effects of miR-34b
is partly through downregulation of the Akt pathway and
EMT markers. We also show that miR-34b inhibits tumor-
igenecity both in vitro and in vivo, this being the first report
documenting the detailed role of miR-34b in prostate
cancer.
One of the most common causes of the loss of tumor
suppressormiRNAs in human cancer is the silencing of their
primary transcripts by CpG island promoter hypermethyla-
tion (17, 27). In fact, DNA methylation–mediated down-
regulation of miRNAs by proximal CpG islands has been
described by a number of groups (16, 17, 28). Further
identification of additional methylation targets may clarify
the specific molecular events involved in prostate cancer
progression, which hopefully will lead to prevention, diag-
nosis, and treatment of prostate cancer at the molecular
Figure 3. Induction of partial
demethylation and active chromatin
modiﬁcations. A, ectopic expression
of miR-34b induces partial
demethylation of CpG islands. B,
enrichment of active chromatin
modiﬁcations by overexpression of
miR-34b. ChIP assay in PC3 cells
transfected with miR-34b or cont-
miR was carried out. Quantiﬁcation
of the immunoprecipitated upstream
region of miR-34b was determined
by qRT-PCR and normalized to input
DNA.Signalswere also conﬁrmedby
conventional PCR, and PCRproduct
for each samplewas resolved on 2%
agarose gel and visualized by
staining with ethidium bromide.
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level. Here, we identified miR-34b is frequently silenced in
tumors comparedwith normal samples and themechanism
of silencing is through DNAmethylation in prostate cancer
tissues. Previous studies have reported CpGmethylation of
miR34b/c in colorectal cancer (16), oral squamous cell
carcinoma (28), malignant melanoma where it correlated
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with metastatic potential (26), and various other cancers
(29). Our study indicates that miR-34b methylation status
can discriminate between normal prostate tissue and cancer
samplesmaking it a potential diagnosticmarker for prostate
cancer. miRNAs possess several features that make them
attractive candidates as new prognostic biomarkers and
tools for the early diagnosis of cancer (13, 30, 31). In this
study, we show that miR-34b expression could predict
overall survival and recurrence-free survival such that
patients with high miR-34b levels had longer survival.
Similarly, promoter hypermethylation of miR-34b/c has
been reported as a common event in non–small cell lung
cancer (NSCLC) and a potential prognostic factor for stage 1
NSCLC. Thus, aberrantDNAmethylation ofmiR-34b/cwas
correlated with a high probability of recurrence and asso-
ciated with poor overall and disease-free survival of patients
with stage I NSCLC (32).
To link altered miR-34b expression with aberrant CpG
methylation, we looked at the ectopic effect of miR-34b on
DNMTs and HDACs because their levels are reported to be
elevated in prostate cancer (33, 34). DNMTs catalyze the
methylation of genomic DNA resulting in transcriptional
repression. DNMTs are also known to recruit HDACs,
leading to histone deacetylation and transcriptional repres-
sion (35, 36). DNMTs and HDACs are expressed at higher
levels in prostate cancer than the nonmalignant prostate
cells although the degree of expression varies among the cell
lines on the basis of the cell context (33, 37, 38). Androgen-
independent cell lines such as Du145 and PC3 express
HDACs at higher levels than androgen-dependent cell lines
such as LNCaP (37). Various reports have shown that
miRNAs downregulate DNMTs (39) and HDACs (40). The
miRNA-29 family directly targets DNMTs and restored
normal patterns of DNA methylation in lung cancer cell
lines (39). Similarly, restoration of miR-9 levels in Wal-
denstrom macroglobulinemia (WM) cells downregulated
HDACs with an upregulation of histone-H3 and –H4 (40).
Further epigenetic regulation of miRNA genes has been
found to be tightly linked to chromatin signatures, and
transcriptionally active miRNA genes are characterized by
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active chromatin marks such as trimethylated histone H3
lysine 4 (3H3K4; 22). Our results showed that miR-34b
suppressed DNMTs and HDACs in prostate cancer cells
resulting in partial demethylation and induction of active
chromatin modifications that are the hallmarks of active
genes. Therefore, downregulation of DNMTs and HDACs
provides positive feedback that result in an active miR-34b
gene (Fig. 6C).
Our study also elucidated the tumor suppressor role and
functional significance of miR-34b in prostate cancer.
Results showed that miR-34b has an antiproliferative effect
and induced G0–G1 cell-cycle arrest and apoptosis. To
determine the antiproliferative and apoptotic effects of
miR-34b, we focused on Akt-GSK-betacatenin-cMyc-Cyclin
D1 proliferative pathway genes. Signaling through PI3K/
Akt pathway controls cell proliferation and apoptosis (41,
42). Aktmediates these effects bymodulating cell-cycle and
apoptosis regulatory proteins (43), and changes in expres-
sion of these genes have been linked to prostate cancer (44).
Other studies have reported that advanced human prostate
cancer was accompanied by the expression of phosphory-
latedAkt (45) and alterations in the serine/threonine kinase
Akt/PKBpathwayhavebeendetected in anumber of human
malignancies (46). Akt has a wide range of downstream
targets that regulate tumor-associated cell processes such as
cell growth, cell-cycle progression, survival, migration,
EMT, and angiogenesis (46). Our results confirmed that
miR-34b directly targeted Akt and caused downregulation
of downstream proteins pGSK, total b-catenin, c-Myc, and
cyclin D1 that are involved in cell proliferation/survival.
These results suggest that the antiproliferative effect of miR-
34b is partly mediated through the Akt pathway. We also
observed a decrease in the migratory and invasive capabil-
ities of prostate cancer cells overexpressing miR-34b and
found that it effected EMT markers. EMT is a multifaceted
transdifferentiation program that enables tumor cells to
acquiremalignancy-associatedphenotypes (47). This initial
step of local invasion may be triggered by signals that
carcinoma cells receive from the nearby stroma, causing
them to undergo an EMT and subsequently metastasize to
distant tissue sites (48). Considerable research has been
focused on identifying the critical regulators of this meta-
static process including both proteins and miRNAs (48).
Our results show that overexpression of miR-34b caused a
decline in the mesenchymal markers vimentin, ZO1, N-
cadherin, and Snail whereas there was an increase in the
expression of E-cadherin, an epithelialmarker. These results
suggest that miR-34b suppresses migration and invasion
independent of cell proliferation and that it has an anti-
metastatic effect on prostate cancer cells.
The antitumorigenic effects of miR-34b observed in this
study were also confirmed in a prostate cancer xenograft
nude mouse model. In vivo experiments showed a striking
suppression in subcutaneous tumor growth in nude mice
where miR-34b was directly administered to tumors com-
pared with controls. Therefore, our study shows that miR-
34b has an important tumor suppressor role both in vitro
and in vivo.
In summary, our study shows that miR-34b is an impor-
tant tumor suppressor that is epigenetically silenced in
prostate cancer. Overexpression of miR-34b reduced
DNMTs and HDACs, inducing partial demethylation and
active chromatin modifications. MiR-34b expression can
also predict overall and recurrence-free survival of patients
with prostate cancer. MiR-34b induces antiproliferative and
anti-invasive effects partly by inhibiting the Akt pathway
and EMT markers. This study documents the pleiotropic
role of miR-34b in prostate cancer. These findings offer
novel insight into the association between dysregulation of
miRNA and methylation/chromatin modification and pro-
vide a strong rationale for the development of new strategies
targeting the epigenetic regulation of miRNAs for the treat-
ment of prostate cancer.
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